Group One Trading’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-21,600
Closed -$2.2M 8562
2023
Q2
$2.2M Sell
21,600
-48,200
-69% -$4.56M 0.01% 1625
2023
Q1
$6.35M Buy
69,800
+56,900
+441% +$3.34M 0.02% 714
2022
Q4
$490K Sell
12,900
-74,800
-85% -$2.57M ﹤0.01% 3064
2022
Q3
$2.2M Buy
87,700
+65,400
+293% +$1.81M ﹤0.01% 1830
2022
Q2
$678K Sell
22,300
-10,700
-32% -$319K ﹤0.01% 3146
2022
Q1
$1.08M Buy
33,000
+16,000
+94% +$475K ﹤0.01% 2996
2021
Q4
$448K Sell
17,000
-21,400
-56% -$1.66M ﹤0.01% 4259
2021
Q3
$3.86M Buy
38,400
+25,000
+187% +$2.93M ﹤0.01% 1975
2021
Q2
$1.9M Buy
13,400
+5,300
+65% +$598K ﹤0.01% 2704
2021
Q1
$808K Buy
8,100
+7,900
+3,950% +$921K ﹤0.01% 3491
2020
Q4
$25K Sell
200
-3,400
-94% -$447K ﹤0.01% 5403
2020
Q3
$351K Sell
3,600
-2,100
-37% -$262K ﹤0.01% 3168
2020
Q2
$889K Sell
5,700
-14,400
-72% -$2.19M ﹤0.01% 2138
2020
Q1
$2.9M Buy
20,100
+15,500
+337% +$2.99M 0.02% 810
2019
Q4
$940K Buy
4,600
+3,600
+360% +$657K 0.01% 1942
2019
Q3
$80K Sell
1,000
-200
-17% -$17K ﹤0.01% 3709
2019
Q2
$113K Hold
1,200
﹤0.01% 3261
2019
Q1
$103K Buy
+1,200
New +$99.6K ﹤0.01% 3154
2018
Q4
Sell
-100
Closed -$8K 5573
2018
Q3
$8K Hold
100
﹤0.01% 4728
2018
Q2
$3K Sell
100
-100
-50% -$3.05K ﹤0.01% 4910
2018
Q1
$4K Buy
+200
New +$5.15K ﹤0.01% 4567

Other funds holding RETA

Group One Trading's RETA Position: Q2 2023 in Review

Group One Trading sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 24,376 shares — an estimated $2.31M sold.

Group One Trading first reported a position in RETA in Q1 2018 and held it in 10 quarters. The position peaked at $2.22M in Q1 2023. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

  • Group One Trading reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
  • Group One Trading sold 24,376 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $2.31M.
  • Group One Trading first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2018 and held it in 10 quarters.
  • Group One Trading's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.22M in Q1 2023.
  • 214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on Group One Trading's 13F filing for Q2 2023, filed 9 Aug 2023.